Ovarian cancer patients denied innovative drug amid cost concerns Cancer charities criticise NHS watchdog’s decision to reject olaparib, which is available elsewhere in Europe
Cancer charities have criticised the decision by the NHS treatment watchdog to reject an innovative new drug to treat ovarian cancer on the grounds of cost.
NICE, the National Institute for Health and Care Excellence, said in draft guidance it was disappointed that it must turn down olaparib (Lynparza), but the price tag of more than £49,000 a year was considerably higher than its ceiling of £20,000 to £30,000. When tests to assess patient suitability for the drug are included, the price rises higher still. Continue reading... The Guardian
See also:
Cancer charities have criticised the decision by the NHS treatment watchdog to reject an innovative new drug to treat ovarian cancer on the grounds of cost.
NICE, the National Institute for Health and Care Excellence, said in draft guidance it was disappointed that it must turn down olaparib (Lynparza), but the price tag of more than £49,000 a year was considerably higher than its ceiling of £20,000 to £30,000. When tests to assess patient suitability for the drug are included, the price rises higher still. Continue reading... The Guardian
See also:
No comments:
Post a Comment